Curative Biotechnology, Inc.

Curative Biotech currently has programs in 3 different therapeutic areas

Degenerative Eye Disease

Neuro Oncology

Infectious Disease

Therapeutic Area
IND Supporting Non-clinical Studies
Rare / Orphan Disease Eligible
Two-Year Inflection Point Milestone
IMT504 Infectious Disease Rabies possible accelerated FDA Marketing Approval
COVID Vaccine with IMT504 Adjuvant Infectious Disease COVID 19 in Kidney Failure Patients operation warpspeed FDA Approved Phase I / II IND
CUBT906 - CD56 Monoclonal Antibody ADC Oncology Glioblastoma possible accelerated FDA Approved Phase I / II IND
Metformin Reformulation Degenerative Eye Disease Age-Related Macular Degeneration 505(b)(2) eligible Completion of Phase I / II Trial